Objective: To report the effects of tesamorelin, a growth hormone-releasing hormone analogue, on inflammatory and fibrinolytic markers and to relate these effects to changes in visceral adipose tissue (VAT).
Introduction
A significant percentage of HIV-infected patients develop increased visceral adipose tissue (VAT) accumulation [1] , and this is seen most clearly in studies in which antiretroviral-naive patients begin HAART [2] . Increased visceral and upper trunk fat are associated with dyslipidemia [3] , insulin resistance [4] , decreased circulating adiponectin [5, 6] , increased rates of subclinical atherosclerosis [7] , and elevated risk of cardiovascular disease (CVD) [8] . Abdominal fat accumulation may also be associated with increased C-reactive protein (CRP) [9] , which is a strong predictor of CVD in HIVinfected individuals [10] . Moreover, individuals with HIV-associated visceral fat accumulation may have impaired fibrinolysis. The hemostatic markers plasminogen activator inhibitor-1 (PAI-1) antigen and tissue plasminogen activator (tPA) antigen are increased in HIVinfected individuals with abdominal obesity compared to controls [5, 11] , and both PAI-1 antigen and tPA antigen are strongly associated with cardiovascular risk in the general population [12] [13] [14] .
We have previously reported that treatment with a novel growth hormone releasing hormone (GHRH) analogue, tesamorelin, for 26 weeks decreases visceral adiposity and increases adiponectin in HIV-infected individuals with abdominal fat accumulation, without significant effects on CRP [15] . As tesamorelin was recently approved by the United States Food and Drug Administration, further information regarding its effects on inflammatory adipokines and hemostatic markers is needed. We hypothesized that the reductions in VAT achieved with tesamorelin would be associated with improvement in circulating hemostatic markers tPA antigen and PAI-1 antigen. Using data from the previously described cohort, we sought to determine the effect of tesamorelin on PAI-1 and tPA antigens in HIV-infected individuals with abdominal adiposity. Moreover, we sought to investigate whether changes in inflammatory markers were related to reductions in VAT controlling for augmentation in growth hormone (GH), as estimated by changes in insulin-like growth factor-1 (IGF-1). Previous reports have indicated that GH treatment decreases tPA antigen in non-HIV-infected individuals [16, 17] , but it has been unclear whether this is a direct effect of GH itself or whether decreased tPA antigen may be mediated by decreased abdominal adiposity. In the current report, we show that long-term treatment with tesamorelin decreases tPA antigen without significantly decreasing PAI-1 antigen, and that changes in tPA, as well as the previously reported increase in adiponectin, appear to be related to reductions in visceral adiposity but not to changes in IGF-1.
Patients and methods

Patients
Four hundred and ten HIV-infected patients (352 men and 58 women, age range: 28-65 years) were recruited at 43 sites between June 2005 and April 2006 to participate in a 26-week placebo-controlled Phase 3 trial to assess the efficacy and safety of tesamorelin in reducing VAT [15] . Patients were randomly assigned in a ratio of 2 : 1 to receive either 2 mg of tesamorelin or matching placebo, administered by subcutaneous injection, for 26 weeks. At 26 weeks, patients initially in the tesamorelin group were re-randomized to either continue tesamorelin (T-T group, N ¼ 154) or receive placebo (T-P group, N ¼ 50) from week 26 to 52. Body composition and metabolic endpoints from this extension phase, including information on CRP and adiponectin, but not tPA antigen or PAI-1 antigen, were previously published [18] .
The primary endpoint of the study was the percentage change from baseline to week 26 in VAT. Eligibility criteria included the receipt of stable antiretroviral therapy (ART) for at least 8 weeks and presence of abdominal fat accumulation, defined as a waist circumference at least 95 cm and waist-to-hip ratio at least 0.94 for men and a waist circumference at least 94 cm and waist-to-hip ratio at least 0.88 for women (for complete eligibility criteria, see Falutz et al. [15] ). Waist circumference and waist-to-hip ratio criteria were based on cutoffs that define increased visceral adiposity (VAT > 130 cm 2 ) in men and women in the general population [19] . The study was approved by the Institutional Review Board at each site, and participants provided written informed consent.
Laboratory methods
VATwas determined by computerized tomography (CT) scan from a single 5-mm slice obtained at the level of L4 and L5 intervertebral disc [15, 20] . Images were read in a blinded fashion at a central imaging reading center (Perceptive Informatics, Waltham, Massachusetts, USA). Inflammatory markers were measured centrally at Gamma-Dynacare (Brampton, Ontario, Canada). Serum PAI-1 antigen and tPA antigen levels were measured from blood samples drawn in citrate, theophylline, adenosine, dipyridamole vacutainers (containing sodium citrate, theophylline, adenosine, and dipyridamole) using ELISA (enzyme-linked immunosorbent assay) kits (Biopool, Umea, Sweden). The intra-assay coefficient of variation for the PAI-1 antigen assay is 3.6-16.9%, and the interassay coefficient of variation is 4.3-6.8%. The intraassay coefficient of variation for the tPA antigen assay is 7.8-9.5%, and the interassay coefficient of variation is 4.6-9.7%. CRP was measured by nephelometry using a BNII analyzer (Siemens Diagnostics, Deerfield, Illinois, USA) with a mean coefficient of variation of 6.4%. Serum adiponectin levels were determined using an ELISA kit (B-Bridge International Inc., Sunnyvale, California, USA); intra-assay coefficient of variation is 3.0-5.3%, and interassay coefficient of variation is 6.3-7.6%. IGF-1 was measured at Esoterix (Calabasas Hills, California, USA).
Statistical analysis
Baseline comparisons between groups were made using an analysis of variance (ANOVA) for continuous variables and Fisher's exact test for noncontinuous variables. The treatment effects were determined using an analysis of covariance (ANCOVA) accounting for baseline and randomization effects as previously described [15] . These analyses were done on the intent-to-treat (ITT) population, which was defined as all randomized participants who were exposed to study drug (i.e., injection of at least one dose of study drug), with the lastobservation-carried-forward for imputation of missing data. To assess the effects of continued tesamorelin or withdrawal from weeks 26-52 on tPA and PAI-1, within group comparisons were performed using repeated measures ANOVA. Spearman's correlations were performed to evaluate the relationships between baseline values and changes from baseline to week 26 in inflammatory markers as well as the relationships between inflammatory markers and VAT or IGF-1, using the ITT population. Partial correlations were used to examine relationships between VAT and inflammatory markers controlling for age, sex, race, BMI, and IGF-1. Partial correlations were also performed to determine the association between changes in inflammatory parameters and changes in VATafter adjustment for change in IGF-1, and separately to determine the association between changes in inflammatory parameters and changes in IGF-1, after adjustment for changes in VAT. Mean AE SD are reported unless otherwise indicated. A P value less than 0.05 was considered significant in all analyses.
Results
Patients
The baseline characteristics of patients enrolled into the study are shown in Table 1 . Body composition, metabolic, inflammatory, and fibrinolytic parameters were similar between the study groups at baseline (all P > 0.05). Mean waist circumference was 104 AE 10 cm, and mean waist-to-hip ratio was 1.05 AE 0.06. Mean CRP was elevated at more than 4 mg/l in both groups. Mean VAT was more than 170 cm 2 in both groups, far exceeding thresholds that have been associated with increased cardiovascular risk [21] [22] [23] .
Relationships between inflammatory markers, visceral adipose tissue, and insulin-like growth factor-1 at baseline At baseline, VAT was positively associated with PAI-1 (r ¼ 0.36, P < 0.001), tPA (r ¼ 0.29, P < 0.001), and CRP (r ¼ 0.18, P < 0.001) in all patients in univariate modeling. An inverse association was found between VAT and adiponectin (r ¼ À0.22, P < 0.001; Table 2 ). When controlling for age, sex, race, and IGF-1 in multivariate modeling, VAT remained significantly associated with PAI-1 antigen (r ¼ 0.35, P < 0.001), tPA antigen (r ¼ 0.24, P < 0.001), and CRP (r ¼ 0.25, P < 0.001), and, inversely, with adiponectin (r ¼ À0.24, P < 0.001). Results were similar when controlling for age, sex, race, IGF-1, and BMI (data not shown).
IGF-1 levels showed weak inverse associations with PAI-1 antigen (r ¼ À0.10, P ¼ 0.04) and tPA antigen (r ¼ À0.10, P ¼ 0.04) concentrations, whereas there was no association between IGF-1 and adiponectin (r ¼ 0.01, P ¼ 0.85) or CRP (r ¼ À0.09, P ¼ 0.09). In exploratory analyses, a quadratic term was added to the models associating IGF-1 with these markers, and there were no significant curvilinear associations with IGF-1 (data not shown).
Changes in visceral adipose tissue and insulin-like growth factor-1 after 26 weeks of tesamorelin administration As previously reported [15] , VAT significantly decreased from baseline to week 26 in tesamorelin-treated patients [À27.8 AE 38.7 cm 2 (À15%) vs. 5 CRP, C-reactive protein; IGF-1, insulin-like growth factor-1; PAI-1, plasminogen activator inhibitor-1; tPA, tissue plasminogen activator; VAT, visceral adipose tissue. a Spearman's rank correlation (r).
(5%), tesamorelin vs. placebo, P < 0.001 vs. placebo, treatment effect, À20.0%] and IGF-1 significantly increased (109 AE 113 vs. À16 AE 66 ng/ml, P < 0.001 vs. placebo). The change in VATwas significantly negatively associated with the change in IGF-1 (r ¼ À0.24, P < 0.001). Effects of tesamorelin on subcutaneous fat and body weight were not seen [15] .
Changes in inflammatory markers after 26 weeks of tesamorelin administration Treatment with tesamorelin was associated with a small but significant decrease in tPA antigen (À2.2 AE 2.5 vs. À1.6 AE 2.9 ng/ml, tesamorelin vs. placebo, P ¼ 0.03) as compared to placebo (Table 3 ). Change in PAI-1 antigen in the tesamorelin group was not significantly different from placebo (À2.5 AE 16.9 vs. À1.0 AE 17.3 ng/ml, tesamorelin vs. placebo, P ¼ 0.34, Table 3 ). As previously reported, adiponectin modestly but significantly increased from baseline in tesamorelin-treated patients (0.5 AE 2.7 vs. À0.1 AE 1.3 mg/ml, tesamorelin vs. placebo, respectively, P ¼ 0.03), and CRP did not significantly change with tesamorelin treatment (Table 3 ) [15] .
Relationships between baseline values and changes in inflammatory markers after 26 weeks of tesamorelin administration
The changes in inflammatory markers were related to the degree of baseline elevation of these markers. Among patients receiving tesamorelin, significant and inverse correlations were found between baseline PAI-1 antigen (r ¼ À0.44, P < 0.001), tPA antigen (r ¼ À0.46, P < 0.001), CRP (r ¼ À0.50, P <0.001), and adiponectin (r ¼ À0.14, P ¼ 0.037) and the change in these variables with 26 weeks of treatment.
Relationships between changes in inflammatory markers and changes in insulin-like growth factor-1 and visceral adipose tissue after 26 weeks of tesamorelin administration Within the tesamorelin group, changes in PAI-1 antigen (r ¼ 0.16, P ¼ 0.02) and tPA antigen (r ¼ 0.16, P ¼ 0.02) were significantly and positively associated with the percentage change in VAT at week 26, and change in adiponectin (r ¼ À0.27, P < 0.001) was inversely related to the change in VAT (Table 4 ). Associations between change in VAT and changes in PAI-1 antigen (P ¼ 0.03), tPA antigen (P ¼ 0.02), and adiponectin (P < 0.001) remained significant when controlling for change in IGF-1, and these relationships also remained significant when using partial correlations controlling for age, race, and sex in addition to change in IGF-1 (data not shown). By contrast, changes in PAI-1 antigen, tPA antigen, and adiponectin were not significantly related to changes in IGF-1, with or without controlling for changes in VAT (Table 4) .
1284 AIDS 2011, Vol 25 No 10 Data are reported as mean AE SD, unless otherwise indicated. CRP, C-reactive protein; PAI-1, plasminogen activator inhibitor-1; tPA, tissue plasminogen activator. a Data previously published in [15] . 1 The values are for the difference between the changes from baseline in the tesamorelin group and the placebo group. 2 The values are for the difference between the percentage change from baseline in the tesamorelin group and the placebo group. 3 P values are for the comparison between the changes from baseline in the tesamorelin group and the placebo group. 4 P < 0.05 for the within-group change from baseline to week 26 within the tesamorelin group and the placebo group. Changes in tissue plasminogen activator and plasminogen activator inhibitor-1 after continued tesamorelin or withdrawal (26-52 weeks) In the extension dataset, significant changes in tPA antigen seen over the first 26 weeks were sustained during weeks 26-52 in the group that continued tesamorelin (T-T group, change from baseline at 52 weeks À2.66 AE 2.60 ng/ml, P < 0.001 for within group comparison). Among the participants discontinuing tesamorelin during weeks 26-52 (T-P group), the change from baseline at 52 weeks in tPA antigen was À2.19 AE 2.22 ng/ml (P < 0.001 for within group comparison). No significant changes were seen in PAI-1 antigen during the extension phase. As previously published, adiponectin showed a sustained increase in the T-T group but returned to baseline in the T-P group, and there were no significant changes in CRP during the extension phase [18] .
Discussion
The current report demonstrates that treatment with the GHRH analogue tesamorelin decreased tPA antigen concentrations in HIV-infected individuals. There were no significant changes in PAI-1 antigen with tesamorelin as compared to placebo. At baseline, higher tPA antigen, higher PAI-1 antigen, and lower adiponectin were associated with VAT in both univariate and multivariate modeling, consistent with previous reports [24] [25] [26] . Changes in PAI-1 and tPA antigens, as well as increased adiponectin [15] , were significantly associated with decreases in VAT, even when controlling for changes in IGF-1, a marker for the effects of tesamorelin on the GH axis. By contrast, there were no strong associations between IGF-1 and inflammatory markers at baseline, and changes in PAI-1 antigen, tPA antigen, and adiponectin were not associated with changes in IGF-1. Taken together, these data suggest that the changes in adiponectin and tPA after tesamorelin treatment may not be due to GH augmentation per se but are likely due to other factors including the effects of tesamorelin to decrease VAT. In addition, these data demonstrate that in addition to reducing VAT, tesamorelin may have additional cardiometabolic benefits in this population by reducing tPA antigen and increasing adiponectin. These effects may be useful for the HIV population, in whom myocardial infarction risk is known to be increased compared to non-HIV-infected controls [27] .
Impaired fibrinolysis may play an important role in the pathophysiology of thrombotic events, and numerous hemostatic markers, including tPA antigen and PAI-1 antigen, are strongly associated with CVD risk in the general population [12, 14] . Although tPA is antithrombotic, dissolving fibrin in the circulation, assays of tPA antigen primarily measure inactive tPA/PAI-1 complexes in the circulation, such that increased tPA antigen levels indicate decreased fibrinolysis [28] . In the general population, increased tPA antigen independently predicts coronary heart disease in models adjusting for conventional cardiovascular risk factors [29, 30] . In HIV-infected patients, Hadigan et al. [11] demonstrated increased tPA antigen levels in HIV-infected individuals with body fat changes compared to non-HIV-infected BMImatched and age-matched controls. In the current report, we extend this observation by demonstrating that tPA antigen levels are strongly associated with VAT in this population, even when controlling for age, sex, race, and IGF-1 levels. Furthermore, we show that tesamorelin significantly decreases tPA antigen in association with reductions in VAT. The magnitude of reduction in the tesamorelin group (À2.2 ng/ml) is similar to that seen after treatment with metformin in this population [11] , although the decrease compared to the placebo group (À2.2 vs. À1.6) is relatively modest and smaller than the difference between metformin and placebo. In contrast to metformin, no effects were seen from tesamorelin on PAI-1. In addition, although it is difficult to directly compare results from this study and the prior unrelated studies of metformin, performed 8 years earlier, fibrinolytic markers appeared less elevated at baseline in the current study. Taken together, these data suggest that metformin, an insulin-sensitizing agent, more robustly decreases fibrinolytic markers than tesamorelin, which also has beneficial though smaller effects. A costbenefit analysis is difficult to perform directly between metformin, which is indicated to improve insulin resistance and is available in generic form, and newly approved tesamorelin, indicated to improve visceral adiposity but not insulin resistance.
Our data demonstrate that favorable changes in tPA antigen are not significantly associated with changes in IGF-1, suggesting that decreased tPA antigen may not be a direct effect of augmenting GH but rather may be mediated, in part, by favorable body composition changes resulting from tesamorelin. We cannot rule out the possibility that other biochemical effects of tesamorelin also contribute to the reduction in tPA antigen. It is unlikely that the changes in tPA and other inflammatory and fibrinolytic markers were due to overall changes in weight or subcutaneous fat, as these body composition parameters did not change in response to tesamorelin, which had a selective effect to reduce VAT. The reductions in tPA antigen seen with tesamorelin treatment persisted to some degree after the switch to placebo during weeks 26-52, despite re-accumulation of VAT in this period, and levels at 52 weeks remained significantly below initial baseline.
PAI-1 antigen levels are strongly associated with visceral adiposity in the general population [26, 31] and are reported to be higher in HIV-infected individuals compared to controls in association with increased visceral adiposity [32] and protease inhibitor use [33] .
In keeping with these reports, our data demonstrate a significant relationship between PAI-1 antigen and visceral fat at baseline. However, PAI-1 antigen did not significantly change in the tesamorelin group compared to the placebo group in this study.
We previously reported that tesamorelin treatment significantly increases adiponectin [15] , and we now show that changes in adiponectin are also strongly associated with changes in VAT but not IGF-1. Adiponectin is known to be inversely associated with visceral adiposity, and adiponectin demonstrates a strong inverse association with CVD [34] [35] [36] in the general population. Further, in animal models, administration of adiponectin demonstrates cardioprotective effects [37, 38] . In HIV-infection, adiponectin is negatively associated with visceral fat and positively associated with limb fat, and adiponectin concentrations are reduced in individuals with lipodystrophic changes compared to HIV-infected controls without body fat changes [39, 40] . In the current study, we demonstrate that a selective reduction in VAT through administration of tesamorelin is significantly associated with improvements in adiponectin in this population. To our knowledge, these are among the first data to demonstrate that a pharmacologic therapy specifically targeted to reduce VAT has the associated effect of increasing adiponectin. We cannot be certain, however, that reduction in VAT is the primary factor contributing to improved adiponectin in the context of tesamorelin treatment. Alternatively, decreases in VAT may be associated with reduction in subclinical inflammation or other factors that subsequently contribute to increased adiponectin concentrations. We do not have data on high molecular weight (HMW) adiponectin, and further studies will be needed to characterize the effects of tesamorelin on the ratio of HMW : total adiponectin.
There are important limitations of the current study. First, the study population consists largely of white male participants. Sex and race were controlled for in analyses, but fibrinolytic markers may differ by sex and race [41, 42] , and further studies will be needed to determine whether the effects of tesamorelin differ according to sex or race. Second, many inflammatory markers show substantial intraindividual variance, which may reduce our ability to characterize changes in these markers over time. In addition, there is a possibility of type I error.
Finally, the changes in inflammatory markers in response to tesamorelin were of relatively small magnitude, and, as the study did not measure clinical cardiovascular endpoints, these changes are of uncertain clinical significance. Moreover, metformin appears to have a larger effect on PAI-1 in this population and may have a more significant effect on tPA [11] . Although tesamorelin should not be used for the primary purpose of improving these markers, modest effects to decrease tPA antigen and increase adiponectin may be relevant associated benefits of its use to reduce VAT.
In summary, our data suggest that tesamorelin decreases tPA antigen and increases adiponectin in association with reductions in VAT. Reductions in tPA persisted after discontinuation of tesamorelin for 6 months, whereas adiponectin levels returned to baseline following withdrawal. Our data do not show a relationship between changes in tPA antigen, PAI-1 antigen, and adiponectin and changes in IGF-1 during the study, suggesting that augmentation of GH may not have a direct effect on these variables. Rather, our data suggest that reductions in VAT in response to tesamorelin contribute to improvement in inflammatory and fibrinolytic markers. Of note, however, IGF-1 levels do not fully reflect changes in GH dynamics, including alterations in pulsatility, so the current analysis does not completely eliminate the possibility that changes in GH dynamics played some role in changes in inflammatory cytokines and fibrinolytic markers. Recent data demonstrate effects of tesamorelin on GH pulsatility in healthy non-HIV individuals [43] , and further studies will be needed to examine relationships between GH pulse characteristics and these variables. Additional studies will also be needed to examine the effects of tesamorelin on other hemostatic markers. These data shed light on the relationship of excess VAT to inflammatory markers in a model of VAT excess in which we show a baseline relationship and a change in response to decreases in VAT. These data also have potential clinical implications and suggest that use of tesamorelin in patients with HIV and excess abdominal fat accumulation may result in an overall improvement in critical inflammatory and fibrinolytic markers, which may improve overall cardiovascular risk.
